Abstract |
High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Twenty-four patients (mean age 6.8 years) were enrolled, 19 underwent HDC/HPCR. Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1). Cytoreduction regimen #1 consisted of carboplatin (500 mg/m(2)) x 3 days, etoposide (250 mg/m(2)) x 3 days, and thiotepa (300 mg/m(2)) x 3 days. Patients without progression or excessive toxicity (n = 11), received regimen #2 with melphalan (60 mg/m(2)) x 3 days and cyclophosphamide (1,500 mg/m(2)) x 4 days. Projected overall/event-free survival for the 19 patients was 51/37% and 34/28% at 1 and 5 years, respectively. Toxicity was significant with six treatment related deaths including four with veno-occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.
|
Authors | Amy Rosenfeld, Morris Kletzel, Reggie Duerst, David Jacobsohn, Paul Haut, Joanna Weinstein, Alfred Rademaker, Colleen Schaefer, Lauren Evans, Molly Fouts, Stewart Goldman |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 97
Issue 2
Pg. 247-55
(Apr 2010)
ISSN: 1573-7373 [Electronic] United States |
PMID | 19768658
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Etoposide
- Cyclophosphamide
- Thiotepa
- Carboplatin
- Melphalan
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Central Nervous System Neoplasms
(mortality, therapy)
- Child
- Child, Preschool
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Infant
- Kaplan-Meier Estimate
- Male
- Melphalan
(administration & dosage, adverse effects)
- Thiotepa
(administration & dosage, adverse effects)
- Transplantation Conditioning
|